Clinical Trial Update: TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing TAC versus TCX as adjuvant therapy for high-risk HER2-negative breast cancer has completed. The update does not provide trial results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TAC regimen
• TCX regimen

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED